Dicot Pharma AB logo

Dicot Pharma AB (KN0)

Market Open
12 Aug, 06:04
XFRA XFRA
0. 01
+0
+4.1667%
61.69M Market Cap
- P/E Ratio
- Div Yield
2,000 Volume
- Eps
0.01
Previous Close
Add Transaction
Day Range
0.01 0.01
Year Range
0.01 0.11
Want to track KN0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

KN0 trading today higher at €0.01, an increase of 4.1667% from yesterday's close, completing a monthly increase of 4.1667% or €0. Over the past 12 months, KN0 stock lost -43.9462%.
KN0 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

KN0 Chart

People also search for

1NL
VRG S.A.
1.24
0%
FUP
Fuji Pharma Co., Ltd.
9.85
+1.0256%
9F9
Elektro Importoren AS
1.88
0%
OFH
Orell Füssli AG
148
0%
0CD
Canatu Oyj
6.35
-3.0534%

Dicot Pharma AB (KN0) FAQ

What is the stock price today?

The current price is €0.01.

On which exchange is it traded?

Dicot Pharma AB is listed on XFRA.

What is its stock symbol?

The ticker symbol is KN0.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 61.69M.

Has Dicot Pharma AB ever had a stock split?

No, there has never been a stock split.

Dicot Pharma AB Profile

Specialty Retail Industry
Consumer Discretionary Sector
Ms. Elin Trampe CEO
XFRA Exchange
SE0011178458 ISIN
SE Country
4 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Dicot AB (publ) is a biopharmaceutical company with a focus on discovering and developing novel treatments for sexual dysfunction, headquartered in Uppsala, Sweden. Founded in 2015, the company has dedicated its efforts to addressing some of the most common yet challenging conditions affecting sexual health, including erectile dysfunction and premature ejaculation. With a strong commitment to improving patients' lives through innovative healthcare solutions, Dicot AB stands at the forefront of pharmaceutical research and development in Sweden.

Products and Services

  • LIB-01

    As the flagship product under development by Dicot AB, LIB-01 is designed to tackle two prevalent sexual health issues: erectile dysfunction and premature ejaculation. This drug aims to provide a comprehensive solution that not only addresses the physiological aspects of these conditions but also the psychological factors that often accompany them. By focusing on the underlying causes of these conditions, LIB-01 represents a pioneering approach within the pharmaceutical industry, distinguishing Dicot AB as an innovator in the field of sexual health treatments.

Contact Information

Address: S:t Olofsgatan 11A, Uppsala, Sweden, 753 21
Phone: 46 7 25 02 10 10